End of the line for Merck's TIGIT, LAG-3 cancer drugs

End of the line for Merck's TIGIT, LAG-3 cancer drugs

Submitted by admin on December 17, 2024 - 11:52am
Source: 
Pharmaphorum
News Tags: 
Merck
vibostolimab
favezelimab
anti-TIGIT
immuno-oncology
Headline: 
End of the line for Merck's TIGIT, LAG-3 cancer drugs
snippet: 

Merck has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

Do Not Allow Advertisers to Use My Personal information